The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index; 5 of the 14 sources its claims cite were checked for support.
Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence
Open accessAbstract
Aims/hypothesis: Glucagon-like peptide 1 (GLP-1) agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors are novel drugs which have recently seen rapid uptake in the treatment of type 2 diabetes and obesity. The paucity of data regarding their safety during pregnancy and lactation causes a dilemma for the physician. The aim of the present study was to systematically review all available data on the offspring effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation. Methods: 2023. Eligible studies investigating the safety (including congenital anomalies, fetal growth, perinatal demise) in animals or humans, or reporting the degree of transfer of these drugs to the fetus, breast milk or breastfed neonate. Two reviewers independently assessed and selected studies for inclusion and subsequently resolved discrepancies by discussion. Results: We included 39 records (n=9 theoretical; based on drug properties, n=7 human; n=23 animal, including 76 human offspring, and an unknown number of animal offspring as these numbers could not be retrieved from the FDA and EMA product information). In animal studies, GLP1-agonists were associated with reduced fetal weight and/or growth, delayed ossification and skeletal variants, usually associated with a reduction in maternal weight gain and decreased food consumption. Exendin-4 (GLP1-agonist) was not transported across the maternal-fetal placental interface. In human studies, exenatide (GLP1-agonist) showed a fetal-to-maternal peptide concentration ratio of ≤ 0.017 in ex vivo human placental perfusion in a single placenta. Liraglutide (GLP1-agonist) showed no significant maternal to fetal transfer at least 3.5 hours after maternal exposure in a human study with one subject. In animal studies, GLP-1 agonists were excreted in breast milk; human data on excretion were not available. In animal studies, SGLT2 inhibitors were generally safe during the first trimester but exposure during postnatal day 21 to 90 in juvenile rats, a period coinciding with the late second and third trimester of human renal development, caused dilatation of the renal pelvis and tubules. Human data consisted of a pharmaceutical database of inadvertent pregnancies during SGLT2 inhibitor use, which found an increase in miscarriages and congenital malformations. In animal studies SGLT2 inhibitors were excreted in breast milk and affected neonatal growth, but human data are not available. Conclusion/interpretation: We found evidence for adverse offspring effects of GLP-1 agonists and SGLT2 inhibitors also in human studies. Our findings broadly support the advice to discontinue GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation, and also support the ongoing registration of pregnancy outcomes in pharmacological databases since the amount of available data is scarce and mostly limited to animal studies. Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=219877.
Overview
CoChat Summary
TL;DR
This systematic review found adverse offspring effects of GLP-1 agonists and SGLT2 inhibitors in animal studies and limited human data, broadly supporting discontinuation during pregnancy and lactation. Available evidence is scarce, mostly animal-based, and human lactation data are absent.
Key findings
- GLP-1 agonists in animal studies were associated with reduced fetal weight/growth, delayed or irregular ossification, skeletal variants, reduced embryonic survival, and major congenital anomalies; semaglutide in rats caused visceral abnormalities and major skeletal malformations. Exendin-4 was not transported across the placenta in healthy pregnant mice, liraglutide showed no significant maternal-to-fetal transfer at least 3.5 hours after exposure in one human subject, and exenatide had a fetal-to-maternal peptide concentration ratio of ≤0.017 in ex vivo human placental perfusion.
- SGLT2 inhibitors were generally not developmentally toxic during first-trimester organogenesis in animals except canagliflozin, which caused metatarsal ossification delays. Exposure on postnatal day 21–90 in juvenile rats, coinciding with late second/third-trimester human renal development, caused dilatation of the renal pelvis and tubules, with reversibility varying by drug. Human pharmaceutical database data found an increase in miscarriages and congenital malformations; for dapagliflozin, 8 reported pregnancy outcomes included 1 congenital hydrocephalus, 2 encephalocele, and 1 infant with talipes, renal aplasia and oesophageal atresia.
- In animal lactation studies, GLP-1 agonists were excreted in milk (exenatide ≤2.5% of maternal plasma; semaglutide 8.3–33%; lixisenatide 9.4%; liraglutide 50%) and caused reduced fetal/neonatal growth. SGLT2 inhibitors were also excreted in animal milk and affected neonatal growth, but no human lactation data were available for either drug class.
- The review included 39 records per the abstract (n=9 theoretical, n=7 human, n=23 animal, including 76 human offspring and an unknown number of animal offspring); the results section separately reports 26 GLP-1 agonist records and 16 SGLT2 inhibitor records.
Methods
- Systematic review searching PubMed, clinicaltrials.gov, FDA and EMA product information from inception up to 19 April 2022 without language restrictions; the search was later updated to include Embase and Cochrane, and the authors contacted the Netherlands Pharmacovigilance Centre Lareb and the Teratology Information Service of Switzerland.
- Eligible studies investigated safety outcomes (congenital anomalies, fetal growth, perinatal demise) in animals or humans, or reported transfer of these drugs to fetus, breast milk, or breastfed neonate; animal and human studies including case reports were included.
- Two reviewers independently selected studies and resolved discrepancies by discussion; one reviewer extracted data and assessed quality, with SYRCLE’s risk of bias tool used for animal studies. Out of 1436 unique records, 1372 were excluded.
Limitations
- Stated: the major limitation is limited availability of both animal and human studies; human studies had small numbers and often lacked data on BMI, age, smoking, drug dose, administration time, and trimester of exposure, and lacked long-term neonatal follow-up.
- Stated: EMA/FDA data extraction was limited to Europe and the USA, so data from other continents were not captured.
- Evident from the text: all included animal studies had a high risk of bias; no human lactation studies were found; and no data were received from Lareb or the Swiss TIS.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 4 Not valid · 12 Not checked · 32 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, a study describing the data in the pharmaceutical company safety databases on pregnant women exposed to glucose lowering drugs including SGLT2 inhibitors was found (46). For Canagliflozin 29 pregnancies were reported of which 14 listed the corresponding pregnancy outcomes:1 congenital anomaly, 2 abortions, 1 fetal demise, 8 normal live births, 2 ongoing pregnancies. For Empagliflozin”
§ Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence > Results > SGLT2 inhibitors during pregnancy
What the sources say
- Supportedcites [46] Benhalima, 2018, The need for appropriate registration of pregnancy outcomes under newer oral glucose-lowering therapies, Diabetes Obes Metab source
The Methods describe searches of pharmaceutical company safety databases for pregnancies exposed to canagliflozin, empagliflozin and dapagliflozin. Table 1 (rendered under Conclusions in our copy) reports pregnancies for all three and lists outcomes including congenital anomalies, abortions, fetal demise and healthy live births. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“None of the SGLT2 inhibitors showed developmental toxicity when a dose not resulting in maternal toxicity was administered during the interval coinciding with the first trimester period of organogenesis except for canagliflozin, where ossification delays of the metatarsal bones were seen ( Table 2 ).”
§ Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence > Results > SGLT2 inhibitors during pregnancy
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In this case, after an uneventful pregnancy, the patient delivered an anatomically normal fetus despite exposure to exenatide during the period of organogenesis.”
§ Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence > Results > GLP-1 agonists during pregnancy
What the sources say
- Not checked — no full text of the sourcecites [33] Williams, 2009, Case report: Exenatide use during pregnancy, Endocrinologist source
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In rats, more severe effects were seen after maternal exposure to semaglutide in the form of visceral abnormalities and major skeletal malformations ( Table 1 ).”
§ Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence > Results > GLP-1 agonists during pregnancy
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Exendin-4 (GLP1-agonist) was not transported across the maternal-fetal placental interface.”
- Also stated in: § GLP-1 agonists during pregnancy · plain
“When healthy pregnant mice were injected once with fluorescence labeled exendin-4 on gestation day 16. One day later, after euthanasia, the exendin-4 was not detected in any of the fetal tissues (fetus, decidua, placenta, fetal membranes) or maternal uterus.”
§ Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § GLP-1 agonists during pregnancy · plain
28 more claims
Create a free account to see all 52 claims and every source verdict.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 10
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An increased risk of malformations was observed for liraglutide and semaglutide at doses comparable to those administered in humans.13–17”
From Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In animal studies, GLP-1RA exposure was associated with reduced fetal growth, delayed skeletal ossification, and reductions in maternal weight gain and food consumption (109).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [109]
The cited source says what the claim attributes to it.
In the citing paper
“According to product labelling, animal studies have indicated a potential for reproductive toxicity at maternally toxic doses for semaglutide, dulaglutide, exenatide and liraglutide.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence > Discussion
“For SGLT-2 inhibitors no studies regarding placental transfer were found.”
§ Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence > Discussion
“The ability to cross the rat placenta has been described as low and very limited for sotagliflozin and empagliflozin respectively.”
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
SYRCLE’s risk of bias tool for animal studies
Hooijmans, C. R., Rovers, M. M., de Vries, R. B., Leenaars, M., Ritskes-Hoitinga, M., & Langendam, M. W. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-43 · Cited by 4,415
Macintosh, M. C. M., Fleming, K. M., Bailey, J. A., Doyle, P., Modder, J., Acolet, D., Golightly, S., & Miller, A. (2006) · BMJ · doi:10.1136/bmj.38856.692986.ae · Cited by 673
Fetal and neonatal outcomes of diabetic pregnancies
Yang, J., Cummings, E. A., OʼConnell, C., & Jangaard, K. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000231688.08263.47 · Cited by 352
Poor pregnancy outcome in women with type 2 diabetes
Clausen, T. D., Mathiesen, E., Ekbom, P., Hellmuth, E., Mandrup-Poulsen, T., & Damm, P. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.323 · Cited by 318
Hawthorne, G., Robson, S., Ryall, E. A., Sen, D., Roberts, S. H., & Platt, M. P. W. (1997) · BMJ · doi:10.1136/bmj.315.7103.279 · Cited by 276
Placental structure, function and drug transfer
Griffiths, S. K., & Campbell, J. P. (2015) · Continuing Education in Anaesthesia Critical Care & Pain · doi:10.1093/bjaceaccp/mku013 · Cited by 272
Perinatal mortality in Type 2 diabetes mellitus
Cundy, T., Gamble, G., Townend, K., Henley, P. G., MacPherson, P., & Roberts, A. B. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00215.x · Cited by 268
Glucagon-like peptide analogues for type 2 diabetes mellitus
Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246
Research works printed but not linked: 1
- Ivanišević, 2018, Pregnancy outcome and liraglutide levels in serum and umbilical vein blood of a woman with type 2 diabetes. A case report, Gynaecol Perinatol, 27
Cited by
2025 ESC Guidelines for the management of cardiovascular disease and pregnancy
De Backer, J., Haugaa, K. H., Hasselberg, N. E., de Hosson, M., Brida, M., Castelletti, S., Cauldwell, M., Cerbai, E., Crotti, L., de Groot, N. M. S., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf193 · Cited by 307
Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020-2023
Lee, J. M., Sharifi, M., Oshman, L. D., Hafez, D., & Chua, K. (2024) · JAMA · doi:10.1001/jama.2024.7112 · Cited by 108
Glucagon-like peptide-1 receptor agonist use in pregnancy: a review
Drummond, R. F., Seif, K. E., & Reece, E. A. (2024) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2024.08.024 · Cited by 110
GLP-1 and Its Analogs: Does Sex Matter?
Börchers, S., & Skibicka, K. P. (2024) · Endocrinology · doi:10.1210/endocr/bqae165 · Cited by 107
Arillotta, D., Floresta, G., Pelletier, G. D. P., Guirguis, A., Corkery, J., Martinotti, G., & Schifano, F. (2024) · Brain Sciences · doi:10.3390/brainsci14060617 · Cited by 77
Metadata
- Authors
- Muller, D. R. P., Stenvers, D. J., Malekzadeh, A., Holleman, F., Painter, R. C., & Siegelaar, S. E.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Amsterdam University Medical Centers (NL)
- Corresponding author
- Muller, Dion R. P.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2023-10-10
- Volume
- 14
- Pages
- 1215356-1215356
- ISSN
- 1664-2392 (ISSN-L)
- PMC
- PMC10597691
- OpenAlex
- W4387477465
- Cited by
- 174
- References
- 41
- Citations by year
- 2026: 63 · 2025: 69 · 2024: 42
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Keywords
- GLP-1 receptor agonists, SGLT2 inhibitors, pregnancy, lactation, drug safety, offspring outcomes, congenital malformations, fetal growth, placental transfer, breast milk excretion, exenatide, exendin-4, liraglutide, dapagliflozin, empagliflozin, drug-induced nephrotoxicity
- MeSH terms
- Liraglutide, Sodium-Glucose Transporter 2 Inhibitors, Exenatide, Animals, Breast Feeding, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Lactation, Placenta, Pregnancy, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. https://app.cochat.ai/papers/10.3389/fendo.2023.1215356
- The paper
- Muller, D. R. P., Stenvers, D. J., Malekzadeh, A., Holleman, F., Painter, R. C., & Siegelaar, S. E. (2023). Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2023.1215356
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
